Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome

Designer receptors exclusively activated by designer drugs (DREADDs) are novel and powerful tools to investigate discrete neuronal populations in the brain. We have used DREADDs to stimulate degenerating neurons in a Down syndrome (DS) model, Ts65Dn mice. Individuals with DS develop Alzheimer's disease (AD) neuropathology and have elevated risk for dementia starting in their 30s and 40s. Individuals with DS often exhibit working memory deficits coupled with degeneration of the locus coeruleus (LC) norepinephrine (NE) neurons. It is thought that LC degeneration precedes other AD-related neuronal loss, and LC noradrenergic integrity is important for executive function, working memory, and attention. Previous studies have shown that LC-enhancing drugs can slow the progression of AD pathology, including amyloid aggregation, oxidative stress, and inflammation. We have shown that LC degeneration in Ts65Dn mice leads to exaggerated memory loss and neuronal degeneration. We used a DREADD, hM3Dq, administered via adeno-associated virus into the LC under a synthetic promoter, PRSx8, to selectively stimulate LC neurons by exogenous administration of the inert DREADD ligand clozapine-N-oxide. DREADD stimulation of LC-NE enhanced performance in a novel object recognition task and reduced hyperactivity in Ts65Dn mice, without significant behavioral effects in controls. To confirm that the noradrenergic transmitter system was responsible for the enhanced memory function, the NE prodrug l-threo-dihydroxyphenylserine was administered in Ts65Dn and normosomic littermate control mice, and produced similar behavioral results. Thus, NE stimulation may prevent memory loss in Ts65Dn mice, and may hold promise for treatment in individuals with DS and dementia.

[1]  J. Moss,et al.  Autism Characteristics and Behavioural Disturbances in ∼ 500 Children with Down's Syndrome in England and Wales , 2014, Autism research : official journal of the International Society for Autism Research.

[2]  M. Ohno,et al.  Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome , 2014, The Journal of Neuroscience.

[3]  S. Isaacson,et al.  Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa , 2014, Vascular health and risk management.

[4]  A. Bittles,et al.  The triple challenges associated with age-related comorbidities in Down syndrome. , 2014, Journal of intellectual disability research : JIDR.

[5]  Ashley M. Fortress,et al.  Nerve growth factor metabolic dysfunction in Down's syndrome brains. , 2014, Brain : a journal of neurology.

[6]  Gary Aston-Jones,et al.  Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia , 2014, Proceedings of the National Academy of Sciences.

[7]  Bill Y. Lin,et al.  Formoterol, a Long-Acting β2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome , 2014, Biological Psychiatry.

[8]  W. Mobley,et al.  Aging and intellectual disability: insights from mouse models of Down syndrome. , 2013, Developmental disabilities research reviews.

[9]  W. Zigman.  Atypical aging in Down syndrome. , 2013, Developmental disabilities research reviews.

[10]  William T. Hu,et al.  Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[11]  C. Ganellin,et al.  The Slow Afterhyperpolarization: A Target of β1-Adrenergic Signaling in Hippocampus-Dependent Memory Retrieval , 2013, The Journal of Neuroscience.

[12]  H. Pape,et al.  Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice , 2013, Biological Psychiatry.

[13]  Gary Aston-Jones,et al.  The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease , 2012, Front. Behav. Neurosci..

[14]  M. Nedergaard,et al.  Norepinephrine: A Neuromodulator That Boosts the Function of Multiple Cell Types to Optimize CNS Performance , 2012, Neurochemical Research.

[15]  Ashley M. Fortress,et al.  Age-Related Neurodegeneration and Memory Loss in Down Syndrome , 2012, Current gerontology and geriatrics research.

[16]  A. Granholm,et al.  Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome , 2011, Behavioural Brain Research.

[17]  T. Arendt,et al.  The cholinergic system in aging and neuronal degeneration , 2011, Behavioural Brain Research.

[18]  S. A. Thomas,et al.  Norepinephrine and ß1-adrenergic signaling facilitate activation of hippocampal CA1 pyramidal neurons during contextual memory retrieval , 2011, Neuroscience.

[19]  Ashley M. Fortress,et al.  Effects of brain‐derived neurotrophic factor on dopaminergic function and motor behavior during aging , 2011, Genes, brain, and behavior.

[20]  S. Lanfranchi,et al.  Executive function in adolescents with Down Syndrome. , 2010, Journal of intellectual disability research : JIDR.

[21]  B. Roth,et al.  Generation of Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) Using Directed Molecular Evolution , 2010, Current protocols in neuroscience.

[22]  M. Shamloo,et al.  Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome , 2009, Science Translational Medicine.

[23]  M. Nicolelis,et al.  Remote Control of Neuronal Activity in Transgenic Mice Expressing Evolved G Protein-Coupled Receptors , 2009, Neuron.

[24]  A. Granholm,et al.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model , 2009, Experimental Neurology.

[25]  B. Roth,et al.  New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug) , 2008, Molecular Pharmacology.

[26]  W. Silverman,et al.  Selective attention deficits associated with mild cognitive impairment and early stage Alzheimer's disease in adults with Down syndrome. , 2008, American journal of mental retardation : AJMR.

[27]  S. Krinsky-McHale,et al.  Dual-task processing as a measure of executive function: a comparison between adults with Williams and Down syndromes. , 2008, American journal of mental retardation : AJMR.

[28]  S. Kalinin,et al.  Noradrenaline deficiency in brain increases β-amyloid plaque burden in an animal model of Alzheimer's disease , 2007, Neurobiology of Aging.

[29]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[30]  A. Tomac,et al.  A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra , 2006, Experimental Neurology.

[31]  Ahmad Salehi,et al.  Increased App Expression in a Mouse Model of Down's Syndrome Disrupts NGF Transport and Causes Cholinergic Neuron Degeneration , 2006, Neuron.

[32]  R. Morris,et al.  Elements of a neurobiological theory of hippocampal function: the role of synaptic plasticity, synaptic tagging and schemas , 2006, The European journal of neuroscience.

[33]  Ming Ouyang,et al.  A requirement for memory retrieval during and after long-term extinction learning. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Freedman,et al.  Learning and memory as a function of age in Down syndrome: A study using animal-based tasks , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  A. Granholm,et al.  Minocycline prevents cholinergic loss in a mouse model of Down's syndrome , 2004, Annals of neurology.

[36]  S. Thomas,et al.  A Distinct Role for Norepinephrine in Memory Retrieval , 2004, Cell.

[37]  A. Nath,et al.  HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat , 2003, Brain Research.

[38]  P. E. Gold,et al.  Diencephalic damage decreases hippocampal acetylcholine release during spontaneous alternation testing. , 2003, Learning & memory.

[39]  A. Granholm,et al.  Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome , 2003, Neuroscience Research.

[40]  A. Granholm,et al.  Behavioral comparison of 4 and 6 month-old Ts65Dn mice: Age-related impairments in working and reference memory , 2003, Behavioural Brain Research.

[41]  C. Cotman,et al.  Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome , 2001, Neurobiology of Disease.

[42]  O. Isacson,et al.  A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. , 2001, Human gene therapy.

[43]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[44]  P. E. Gold,et al.  Intrahippocampal Infusions of K-ATP Channel Modulators Influence Spontaneous Alternation Performance: Relationships to Acetylcholine Release in the Hippocampus , 2001, The Journal of Neuroscience.

[45]  Robert E. Clark,et al.  Impaired Recognition Memory in Rats after Damage to the Hippocampus , 2000, The Journal of Neuroscience.

[46]  A. Granholm,et al.  Loss of Cholinergic Phenotype in Basal Forebrain Coincides with Cognitive Decline in a Mouse Model of Down's Syndrome , 2000, Experimental Neurology.

[47]  D. Selkoe,et al.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. , 2000, The American journal of pathology.

[48]  Michael E. Ragozzino,et al.  Modulation of Hippocampal Acetylcholine Release and Spontaneous Alternation Scores by Intrahippocampal Glucose Injections , 1998, The Journal of Neuroscience.

[49]  R. Palmiter,et al.  Disruption of the dopamine β-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory , 1997 .

[50]  J. Sarvey,et al.  LTP in the lateral perforant path is β‐adrenergic receptor‐dependent , 1997 .

[51]  M. Dierssen,et al.  A behavioral assessment of Ts65Dn mice: a putative Down syndrome model , 1995, Neuroscience Letters.

[52]  Wade K. Smith,et al.  Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.

[53]  M. Nakamura,et al.  Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa. , 1987, Biochemical pharmacology.

[54]  P. Yates,et al.  A comparison of nerve cell loss in cortical and subcortical structures in Alzheimer's disease. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[55]  J. Sarvey,et al.  Depletion of norepinephrine, but not serotonin, reduces long-term potentiation in the dentate gyrus of rat hippocampal slices , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[56]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[57]  R. Moore,et al.  Noradrenergic innervation of the adult rat hippocampal formation , 1980, The Journal of comparative neurology.

[58]  J. Clark,et al.  Behavioral assessment. , 1977, Oral health.

[59]  S. Isaacson,et al.  Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa , 2014 .

[60]  G. Aston-Jones,et al.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. , 2011, Journal of Alzheimer's disease : JAD.

[61]  C. Cotman,et al.  Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. , 2001, Neurobiology of disease.

[62]  J. Sarvey,et al.  LTP in the lateral perforant path is beta-adrenergic receptor-dependent. , 1997, Neuroreport.

[63]  R. Palmiter,et al.  Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. , 1997, Behavioral neuroscience.

[64]  M. Davisson,et al.  Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. , 1990, Progress in clinical and biological research.